RxDoctor Payments Data

David Bridgers, MD

Internal Medicine · Irmo, SCNPI 1982696829

Payments from drug & device makers

$5,999in general payments, 2019–2025

Across 353 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$737
  • Novo Nordisk$543
  • AbbVie$510
  • Amgen$411
  • Axsome Therapeutics, Inc.$300
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$289
  • plus $3K from 44 others

What the payments were for

  • Food & beverage$5,88498%
  • Other$1162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,999 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$334,050
Medicare patients
464
Services billed
10,613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide115$160,386
MounjaroTirzepatide100$118,018
EliquisApixaban89$110,706
JanuviaSitagliptin Phosphate34$36,837
FarxigaDapagliflozin Propanediol35$33,667
TrulicityDulaglutide26$32,386
JardianceEmpagliflozin21$31,681
XareltoRivaroxaban21$19,112
MyrbetriqMirabegron13$16,079
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$14,133
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$13,488
Atorvastatin Calcium378$6,818
Olmesartan Medoxomil130$4,830
Levothyroxine Sodium278$4,496
Celecoxib87$3,984

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$543$160,386115 claims
Lilly USA, LLCMounjaro, Trulicity$165$150,404126 claims
PfizerEliquis$80$110,70689 claims
MerckJanuvia$47$36,83734 claims
AstraZenecaFarxiga$737$33,66735 claims
Boehringer IngelheimJardiance$28$31,68121 claims
Johnson & JohnsonXarelto$25$19,11221 claims
Astellas Pharma US IncMyrbetriq$78$16,07913 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$4,496278 claims
AbbVieSynthroid$510$3,06932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Irmo

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →